查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1516707

TCR 療法的全球市場管道

Global Tcr Therapy Market Pipeline
出版日期: | 出版商: Inkwood Research | 英文 290 Pages | 商品交期: 2-3個工作天內

價格

主要發現

TCR療法（T細胞受體療法）是一種創新的免疫療法，利用人體自身的免疫系統來對抗癌症。在這種方法中，患者的 T 細胞被提取並表達專門設計用於識別並結合腫瘤細胞上 MHC（主要組織相容性複合物）所呈現的癌症相關抗原的受體。

與針對細胞表面抗原的 CAR-T 療法不同，TCR 療法可以針對細胞內蛋白質，從而能夠針對更廣泛的癌症。經過改造後，T 細胞會在實驗室中擴增並重新註射到患者體內，在那裡它們會尋找並摧毀癌細胞。TCR 療法在治療包括實體腫瘤在內的各種癌症方面顯示出前景，目前正在進行廣泛的研究以優化其療效和安全性。

市場洞察

全球 TCR 治療市場成長的主要驅動力

  • 有前途的臨床和臨床前研究的增加
  • 癌症發生率上升

根據美國癌症協會預測，2023年美國將新增1,958,310例癌症病例，609,820人死亡。癌症發生率的上升凸顯了對更有效治療方法的迫切需要，將 TCR（T 細胞受體）療法推向了前沿。隨著全球癌症發病率飆升，對 TCR 等創新療法的需求不斷增長，這種療法利用免疫系統來針對癌細胞。

隨著越來越多的患者被診斷出患有各種形式的癌症，TCR 療法的市場自然會擴大，以解決這些不同的適應症。這一趨勢證明了 TCR 療法的多功能性及其滿足癌症患者不斷變化的需求的潛力，使其成為腫瘤學領域的關鍵參與者。

隨著越來越多的患者需要先進的治療方案，TCR 療法專門針對癌細胞的能力使其成為有前景的解決方案。TCR療法對多種癌症類型的適用性進一步增加了其吸引力，使其成為持續對抗癌症的關鍵要素，並為癌症治療提供了充滿希望的未來前景。

  • 技術創新和研究活動迅速增加

全球TCR治療市場的主要成長限制因素

  • TCR 治療中的細胞激素風暴毒性
  • TCR 基因轉殖中的脫靶效應與安全問題
  • 選擇最佳標靶抗原的課題

需要適當的 HLA 匹配，因為 T 細胞受體 (TCR) 只能識別肽-HLA 複合物，並且對 HLA 等位基因匹配的癌細胞有效。這意味著非中國來源的TCR-T細胞不能直接應用於中國患者。識別具有最佳親和力閾值的 TCR 的篩選過程具有課題性，因為需要高親和力 TCR 來增強免疫反應。

鑑定對抗原具有高親和力的 TCR 對於有效的免疫反應至關重要，但必須仔細調節這種親和力。當 TCR 親和力超過生理極限時，T 細胞可能會受傷。

表達TCR的T細胞辨識抗原的機制對於T細胞免疫至關重要。T 細胞必須對病原體呈現的抗原做出定量反應，同時不對宿主組織上的類似抗原做出反應。

TCR療法｜概述

  • 介紹
  • TCR的結構特點
  • 預選曲目中的 TCR 多樣性

T 細胞受體 (TCR) 的預選庫由遺傳因子和表觀遺傳因子共同決定。根據可及性假說，基因片段必須能夠被重組機制所訪問，其中涉及核重排、DNA甲基化、染色質重塑、組蛋白修飾和種系轉錄等過程。

最近的分析表明，框架外 TCR-a 序列的頻率受到 V 和 J 片段使用的影響，表明存在遺傳影響。此外，在胸腺選擇之前，重組偏差會促使同基因小鼠的 TCR-B 鏈庫出現顯著冗餘，突顯透過 V(D)J 重組顯著塑造 TCR 庫組成的傾向。

  • NP 中的 TCR 多樣性
  • 健康和疾病中的 TCR 多樣性
  • TCR 克隆型作為疾病標記物
  • TCR複合物
  • TCR輔助受體
  • TCR複合體參與T細胞活化的相關分子
  • T細胞受體修飾的T細胞用於癌症治療：現況與未來方向
  • TCR序列鑑定
  • 改善腫瘤微環境中 TCR 修飾的 T 細胞的功能

競爭考慮

全球 TCR 治療市場的主要參與者

  • Adaptimmune
  • Gilead Sciences
  • Alaunos Therapeutics
  • Triumvira Immunologics
  • Takara Bio

我們提供 10% 免費客製化和 3 個月的分析師支援。

常見問題（FAQ）：

  • TCR 療法如何發揮作用？

答：TCR 療法包括從患者體內提取T 細胞，對它們進行基因改造，使其表達能夠識別癌症相關抗原的特定T 細胞受體(TCR)，然後將這些經過修飾的T 細胞注射到患者體內，透過重新接種疫苗來發揮作用。然後，這些經過修飾的 T 細胞會瞄準並殺死表現出特定抗原的癌細胞。

  • TCR 療法有哪些風險和副作用？

答：TCR 療法的常見風險和副作用包括細胞激素釋放症候群 (CRS)、神經毒性和可能損害健康組織的脫靶效應。這些副作用需要在治療期間和治療後仔細監測和管理。

  • TCR療法和CAR-T療法有何不同？

答：TCR療法和CAR-T療法都是對T細胞進行基因修飾，但其標靶辨識機制不同。CAR-T細胞透過嵌合抗原受體辨識癌細胞上的表面抗原，而TCR療法則針對MHC分子呈現的細胞內抗原。這使得 TCR 療法能夠靶向更廣泛的癌症相關蛋白。

目錄

第一章簡介

第 2 章 TCR 治療：概述

第三章概述

  • 介紹
  • TCR的結構特點
  • 預選曲目中的 TCR 多樣性
  • NP 中的 TCR 多樣性
  • 健康和疾病中 TCR 的多樣性
  • TCR 克隆型作為疾病標記物
  • TCR複合物
  • TCR輔助受體
  • TCR複合體參與T細胞活化的相關分子
  • T細胞受體修飾的T細胞用於癌症治療：現況與未來方向
  • TCR序列的鑑定
  • 改善腫瘤微環境中 TCR 修飾的 T 細胞的功能

第四章市場動態

  • 主要驅動因素
    • 有前途的臨床和臨床前研究的增加
    • 癌症發生率上升
    • 技術創新和研究活動迅速增加
  • 主要限制因素
    • TCR 治療中的細胞激素風暴毒性
    • TCR 基因轉殖中的脫靶效應與安全問題
    • 選擇最佳標靶抗原的課題

第五章管道處理

  • 目前管道概述
  • 比較分析：各階段產品

第六章治療評估：有效的產品

  • 依給藥途徑評價
  • 依階段和給藥途徑進行評價
  • 依分子類型評估
  • 依階段/分子類型評估
  • 依產品類型劃分的評級
  • 依階段/產品類型評估
  • 依治療區域評估
  • 依階段/治療區域進行評估

第七章 後期產品（預先註冊）

  • 比較分析
  • ADP-A2M4：ADAPTIMMUNE
    • 產品描述
    • 研究與開發
    • 安全性/有效性
    • 產品/開發活動

第八章 後期產品（第三期）

  • 比較分析
  • IMC F106C：IMMUNOCORE
    • 產品描述
    • 研究與開發
    • 安全性/有效性
    • 產品/開發活動

第9章：中期產品（II/III期）

  • 比較分析
  • IMC-GP100：IMMUNOCORE
    • 產品描述
    • 研究與開發
    • 產品/開發活動

第10章：中期產品（二期）

  • 比較分析
  • TAEST 16001：GUANGDONG XIANGXUE PRECISION MEDICAL TECHNOLOGY CO LTD
    • 產品描述
    • 研究與開發
    • 安全性/有效性
    • 產品/開發活動
  • GSK 3377794：GLAXOSMITHKLINE
    • 產品描述
    • 研究與開發
    • 安全性/有效性
    • 產品/開發活動
  • ALT-801：ALTIMMUNE
    • 產品描述
    • 研究與開發
    • 產品/開發活動
  • KITE-439：GILEAD SCIENCES
    • 產品描述
    • 研究與開發
    • 安全性/有效性
    • 產品/開發活動
  • KITE-718：GILEAD SCIENCES
    • 產品描述
    • 研究與開發
    • 產品/開發活動

第十一章 早期產品（I/II 期）

  • 比較分析
  • TC-510：ADAPTIMMUNE
    • 產品描述
    • 研究與開發
    • 產品/開發活動
  • TCR-T LIBRARY：ALAUNOS THERAPEUTICS INC
    • 產品描述
    • 研究與開發
    • 安全性/有效性
    • 產品/開發活動
  • SCG101：SCG CELL THERAPY
    • 產品描述
    • 研究與開發
    • 安全性/有效性
  • TK-8001：T-KNIFE GMBH
    • 產品描述
    • 研究與開發
    • 安全性/有效性
    • 產品/開發活動
  • ECT 204：JW THERAPEUTICS
    • 產品描述
    • 研究與開發
    • 產品/開發活動
  • JWATM 203：JW THERAPEUTICS
    • 產品描述
    • 產品/開發活動
  • IMC I109V：IMMUNOCORE
    • 產品描述
    • 研究與開發
    • 安全性/有效性
    • 產品/開發活動
  • IMCM113V：IMMUNOCORE
    • 產品描述
    • 安全性/有效性
    • 產品/開發活動
  • MDG 1011：MEDIGENE AG
    • 產品描述
    • 安全性/有效性
    • 產品/開發活動
  • TC-210：ADAPTIMMUNE THERAPEUTICS
    • 產品描述
    • 研究與開發
    • 安全性/有效性
    • 產品/開發活動
  • TC-110：ADAPTIMMUNE THERAPEUTICS
    • 產品描述
    • 研究與開發
    • 安全性/有效性

第十二章產品/開發活動

  • TBI 1301：TAKARA BIO
    • 產品描述
    • 研究與開發
    • 安全性/有效性
    • 產品/開發活動
  • IMA402：IMMATICS
    • 產品描述
    • 研究與開發
    • 安全性/有效性
    • 產品/開發活動
  • TAC01 HER2：TRIUMVIRA
    • 產品描述
    • 研究與開發
    • 安全性/有效性
  • TAC01 CLDN18.2：TRIUMVIRA
    • 產品描述
    • 研究與開發
    • 安全性/有效性
  • HBV ANTIGEN SPECIFIC TCR REDIRECTED T-CELL：LION TCR
    • 產品描述
    • 研究與開發
    • 安全性/有效性
    • 產品/開發活動
  • TC-E202：TCRCURE BIOTECH
    • 產品描述
    • 研究與開發
    • 產品/開發活動

第 13 章早期產品（第一階段）

  • 比較分析
  • TSC-100：TSCAN THERAPEUTICS
    • 產品描述
    • 研究與開發
    • 安全性/有效性
  • TSC-200：TSCAN THERAPEUTICS
    • 產品描述
    • 研究與開發
  • IMA201：IMMATICS
    • 產品描述
    • 研究與開發
  • IMA203：IMMATICS
    • 產品描述
    • 研究與開發
    • 安全性/有效性
  • ADP-A2M10：ADAPTIMMUNE
    • 產品描述
    • 研究與開發
    • 安全性/有效性
    • 產品開發活動
  • ADP-A2AFP：ADAPTIMMUNE
    • 產品描述
    • 研究與開發
    • 安全性/有效性
    • 產品開發活動
  • CMV TCR-T：CHINA IMMUNOTECH
    • 產品描述
    • 研究與開發
    • 安全性/有效性
  • IMA401：IMMATICS
    • 產品描述
    • 研究與開發
    • 安全性/有效性
    • 產品開發活動
  • BNT221：BIONTECH
    • 產品描述
    • 研究與開發
    • 安全性/有效性
  • NT 125：NEOGENE THERAPEUTICS
    • 產品描述
    • 產品開發活動
  • NT-175：NEOGENE THERAPEUTICS
    • 產品描述
    • 研發內容
    • 產品開發活動
  • LYL-845：LYELL IMMUNOPHARMA
    • 產品描述
    • 研究與開發
  • BRL03：BIOSYNGEN
    • 產品描述
  • TSC 101：TSCAN THERAPEUTICS
    • 產品描述
    • 研究與開發
    • 安全性/有效性
  • AB-1015：ARSENALBIO
    • 產品描述
    • 研究與開發
    • 安全性/有效性
  • TSC 204：TSCAN THERAPEUTICS
    • 產品描述
    • 研究與開發
  • TSC 203：TSCAN THERAPEUTICS
    • 產品描述
    • 產品開發活動
  • 800 TCR：T-CUR
    • 產品描述
    • 研究與開發
    • 產品開發活動
  • 820 TCR：T-CUR
    • 產品描述
    • 研究與開發

第14章 IND階段的產品

  • 比較分析

第十五章 臨床前階段產品

  • 比較分析

第 16 章發現階段產品

  • 比較分析

第 17 章非活躍產品

  • 比較分析

第十八章 戰略發展

  • 合併/收購
  • 合夥/合約

第19章未滿足的需求

Product Code: 90769

KEY FINDINGS

TCR therapy, or T-cell receptor therapy, is an innovative form of immunotherapy that leverages the body's own immune system to combat cancer. This approach involves extracting a patient's T-cells and genetically engineering them to express receptors specifically designed to recognize and bind to cancer-associated antigens presented by the major histocompatibility complex (MHC) on tumor cells.

Unlike CAR-T therapy, which targets antigens on the cell surface, TCR therapy can target intracellular proteins, allowing for a broader range of cancer targets. Once engineered, these T-cells are expanded in the laboratory and reinfused into the patient, where they seek out and destroy cancer cells. TCR therapy holds significant promise for treating various cancers, including solid tumors, and is currently the focus of extensive research to optimize its efficacy and safety.

MARKET INSIGHTS

Key enablers of the global TCR therapy market growth:

  • Growing number of promising clinical and preclinical studies
  • Rising cancer incidence rates

According to the American Cancer Society, the United States is projected to see 1,958,310 new cancer cases and 609,820 cancer deaths in 2023. The rising incidence of cancer underscores the urgent need for more effective treatments, propelling TCR (T-cell receptor) therapy into the forefront. As cancer rates surge globally, the demand for innovative therapies like TCR, which harnesses the immune system to target cancer cells, is increasing.

With more patients being diagnosed with various forms of cancer, the market for TCR therapy naturally expands to address these diverse indications. This trend showcases the versatility of TCR therapy and its potential to meet the evolving needs of cancer patients, positioning it as a significant player in the field of oncology.

As more patients require advanced therapeutic options, TCR therapy's ability to specifically target cancer cells positions it as a promising solution. Its adaptability across different cancer types enhances its appeal, making TCR therapy a crucial component in the ongoing battle against cancer and a key factor in the future landscape of oncology treatments.

  • Surge in innovation and research activities

Key growth restraining factors of the global TCR therapy market:

  • Toxicity from cytokine storms in TCR therapy
  • Off-target effects and safety concerns in TCR gene transfer
  • Challenges in selecting the optimal target antigen

T-cell receptors (TCRs) can only recognize peptide-HLA complexes and are effective against cancer cells that have matching HLA alleles, necessitating appropriate HLA matching. This means that TCR-T-cells derived from non-Chinese individuals cannot be directly applied to Chinese patients. The screening process for identifying TCRs with the optimal affinity threshold is challenging, as high-affinity TCRs are needed to enhance immune responses.

Identifying TCRs with high affinity for antigens is crucial for effective immune responses, but the affinity must be carefully regulated. If TCR affinity exceeds physiological limits, it can result in injury to the T-cells.

The mechanism of antigen recognition by TCR-expressing T-cells is vital for T-cell immunity. T-cells must quantitatively respond to antigens presented by pathogens while remaining unresponsive to similar antigens on host tissues.

TCR Therapy | Overview

  • Introduction
  • Structural characteristics of the TCR
  • TCR diversity in the pre-selection repertoire

The pre-selection repertoire of T-cell receptors (TCRs) is shaped by both genetic and epigenetic factors. According to the accessibility hypothesis, gene segments must be accessible to recombination machinery, involving processes such as subnuclear relocation, DNA methylation, chromatin remodeling, histone modification, and germline transcription.

Although the activation of the 3' proximal region of antigen receptor loci is well understood, the mechanisms controlling the accessibility and activation of the 5' V region remain unclear. Research has shown that V genes in the immunoglobulin heavy chain locus recombine at different frequencies even when they have equal accessibility, implying that similar biases might also be present in TCR loci.

Recent analyses reveal that the frequency of out-of-frame TCR-a sequences is affected by the usage of V and J segments, indicating a genetic influence. Additionally, recombination bias causes a notable overlap in the TCR-B chain repertoire among syngeneic mice before thymic selection, highlighting a predisposition in the TCR repertoire composition that is significantly shaped by V(D)J recombination.

  • TCR diversity in the naive pool
  • TCR diversity in health and disease
  • TCR clonotypes as markers of disease
  • The TCR complex

The TCR receptor complex is an octameric structure with three dimeric signaling modules: CD247 ζ/ζ, CD3δ/ε, and CD3Y/ε, and variable a and B chains. Ionizable residues in the transmembrane domains stabilize the complex, while signaling molecules are essential due to the TCR's short cytoplasmic tail.

TCRs exhibit low affinity for peptide/MHC ligands (dissociation constants of 1-100 μM); but T-cells maintain high antigen specificity and sensitivity through the formation of TCR microclusters, enhancing antigen recognition via an avidity-based mechanism.

Antigen-experienced T-cells (effector and memory) show increased sensitivity and require fewer costimulatory signals and lower antigen concentrations compared to naive T-cells, achieved through functional avidity maturation without changes in affinity.

  • TCR co-receptors
  • Associated molecules of the TCR complex involved in T-cell activation
  • T-cell receptor-engineered T-cells for cancer treatment: Current status and future directions
  • Identification of TCR sequences
  • Improving the function of TCR-engineered T-cells in tumor microenvironment

COMPETITIVE INSIGHTS

Major players in the global TCR therapy market:

  • Adaptimmune
  • Gilead Sciences
  • Alaunos Therapeutics
  • Triumvira Immunologics
  • Takara Bio

Gilead Sciences, a biopharmaceutical company established in 1987 in Foster City, California, specializes in researching, developing, and marketing medicines for life-threatening diseases. With over 7,000 employees spread across offices on six continents, Gilead focuses on therapeutic areas such as HIV/AIDS, hepatitis B and C, influenza, COVID-19, liver diseases, hematology, and oncology. Some of their notable products include Biktarvy, Complera, Descovy, Emtriva, Genvoya, Odefsey, Stribild, and Sunlenca.

KITE-439, developed by Gilead Sciences, is a T lymphocyte replacement therapy. Preclinical studies have shown efficacy with MHC class I-restricted T-cell receptor (TCR)-engineered T-cells targeting the E7 protein on HPV16-positive tumor cells. The drug is currently in Phase II clinical trials for the treatment of both solid and hematological malignancies.

We Offer 10% Free Customization and 3 Months Analyst Support

Frequently Asked Questions (FAQs):

  • How does TCR therapy work?

A: TCR therapy works by extracting T-cells from a patient, genetically engineering them to express specific T-cell receptors (TCRs) that can recognize cancer-associated antigens, and then reinfusing these modified T-cells back into the patient. These engineered T-cells then target and kill cancer cells displaying the specific antigen.

  • What are the risks and side effects of TCR therapy?

A: Common risks and side effects of TCR therapy include cytokine release syndrome (CRS), neurotoxicity, and potential off-target effects that might damage healthy tissues. These side effects necessitate careful monitoring and management during and after treatment.

  • How is TCR therapy different from CAR-T therapy?

A: While both TCR and CAR-T therapies involve genetically modifying T-cells, they differ in their target recognition mechanisms. CAR-T-cells recognize surface antigens on cancer cells through chimeric antigen receptors, whereas TCR therapy targets intracellular antigens presented by MHC molecules. This allows TCR therapy to target a broader range of cancer-associated proteins.

TABLE OF CONTENTS

1. INTRODUCTION TO THE REPORT

2. TCR THERAPY: SUMMARY

3. OVERVIEW

  • 3.1. INTRODUCTION
  • 3.2. STRUCTURAL CHARACTERISTICS OF THE TCR
  • 3.3. TCR DIVERSITY IN THE PRE-SELECTION REPERTOIRE
  • 3.4. TCR DIVERSITY IN THE NAIVE POOL
  • 3.5. TCR DIVERSITY IN HEALTH AND DISEASE
  • 3.6. TCR CLONOTYPES AS MARKERS OF DISEASE
  • 3.7. THE TCR COMPLEX
  • 3.8. TCR CO-RECEPTORS
  • 3.9. ASSOCIATED MOLECULES OF THE TCR COMPLEX INVOLVED IN T-CELL ACTIVATION
  • 3.10. T-CELL RECEPTOR-ENGINEERED T-CELLS FOR CANCER TREATMENT: CURRENT STATUS AND FUTURE DIRECTIONS
  • 3.11. IDENTIFICATION OF TCR SEQUENCES
  • 3.12. IMPROVING THE FUNCTION OF TCR-ENGINEERED T-CELLS IN TUMOR MICROENVIRONMENT

4. MARKET DYNAMICS

  • 4.1. KEY DRIVERS
    • 4.1.1. GROWING NUMBER OF PROMISING CLINICAL AND PRECLINICAL STUDIES
    • 4.1.2. RISING CANCER INCIDENCE RATES
    • 4.1.3. SURGE IN INNOVATION AND RESEARCH ACTIVITIES
  • 4.2. KEY RESTRAINTS
    • 4.2.1. TOXICITY FROM CYTOKINE STORMS IN TCR THERAPY
    • 4.2.2. OFF-TARGET EFFECTS AND SAFETY CONCERNS IN TCR GENE TRANSFER
    • 4.2.3. CHALLENGES IN SELECTING THE OPTIMAL TARGET ANTIGEN

5. PIPELINE THERAPEUTICS

  • 5.1. CURRENT PIPELINE OVERVIEW
  • 5.2. COMPARATIVE ANALYSIS: PRODUCTS IN VARIOUS PHASES

6. THERAPEUTIC ASSESSMENT: ACTIVE PRODUCTS

  • 6.1. EVALUATION BY ROUTE OF ADMINISTRATION
  • 6.2. EVALUATION BY STAGE AND ROUTE OF ADMINISTRATION
  • 6.3. EVALUATION BY MOLECULE TYPE
  • 6.4. EVALUATION BY STAGE AND MOLECULE TYPE
  • 6.5. EVALUATION BY PRODUCT TYPE
  • 6.6. EVALUATION BY STAGE AND PRODUCT TYPE
  • 6.7. EVALUATION BY THERAPY AREA
  • 6.8. EVALUATION BY STAGE AND THERAPY AREA

7. LATE-STAGE PRODUCTS (PRE-REGISTRATION)

  • 7.1. COMPARATIVE ANALYSIS
  • 7.2. ADP-A2M4: ADAPTIMMUNE
    • 7.2.1. PRODUCT DESCRIPTION
    • 7.2.2. RESEARCH AND DEVELOPMENT
    • 7.2.3. SAFETY AND EFFICACY
    • 7.2.4. PRODUCT AND DEVELOPMENTAL ACTIVITIES

8. LATE-STAGE PRODUCTS (PHASE III)

  • 8.1. COMPARATIVE ANALYSIS
  • 8.2. IMC F106C: IMMUNOCORE
    • 8.2.1. PRODUCT DESCRIPTION
    • 8.2.2. RESEARCH AND DEVELOPMENT
    • 8.2.3. SAFETY AND EFFICACY
    • 8.2.4. PRODUCT AND DEVELOPMENTAL ACTIVITIES

9. MID-STAGE PRODUCTS (PHASE II/III)

  • 9.1. COMPARATIVE ANALYSIS
  • 9.2. IMC-GP100: IMMUNOCORE
    • 9.2.1. PRODUCT DESCRIPTION
    • 9.2.2. RESEARCH AND DEVELOPMENT
    • 9.2.3. PRODUCT AND DEVELOPMENTAL ACTIVITIES

10. MID-STAGE PRODUCTS (PHASE II)

  • 10.1. COMPARATIVE ANALYSIS
  • 10.2. TAEST 16001: GUANGDONG XIANGXUE PRECISION MEDICAL TECHNOLOGY CO LTD
    • 10.2.1. PRODUCT DESCRIPTION
    • 10.2.2. RESEARCH AND DEVELOPMENT
    • 10.2.3. SAFETY AND EFFICACY
    • 10.2.4. PRODUCT AND DEVELOPMENTAL ACTIVITIES
  • 10.3. GSK 3377794: GLAXOSMITHKLINE
    • 10.3.1. PRODUCT DESCRIPTION
    • 10.3.2. RESEARCH AND DEVELOPMENT
    • 10.3.3. SAFETY AND EFFICACY
    • 10.3.4. PRODUCT AND DEVELOPMENTAL ACTIVITIES
  • 10.4. ALT-801: ALTIMMUNE
    • 10.4.1. PRODUCT DESCRIPTION
    • 10.4.2. RESEARCH AND DEVELOPMENT
    • 10.4.3. PRODUCT AND DEVELOPMENTAL ACTIVITIES
  • 10.5. KITE-439: GILEAD SCIENCES
    • 10.5.1. PRODUCT DESCRIPTION
    • 10.5.2. RESEARCH AND DEVELOPMENT
    • 10.5.3. SAFETY AND EFFICACY
    • 10.5.4. PRODUCT AND DEVELOPMENTAL ACTIVITIES
  • 10.6. KITE-718: GILEAD SCIENCES
    • 10.6.1. PRODUCT DESCRIPTION
    • 10.6.2. RESEARCH AND DEVELOPMENT
    • 10.6.3. PRODUCT AND DEVELOPMENTAL ACTIVITIES

11. EARLY-STAGE PRODUCTS (PHASE I/II)

  • 11.1. COMPARATIVE ANALYSIS
  • 11.2. TC-510: ADAPTIMMUNE
    • 11.2.1. PRODUCT DESCRIPTION
    • 11.2.2. RESEARCH AND DEVELOPMENT
    • 11.2.3. PRODUCT AND DEVELOPMENTAL ACTIVITIES
  • 11.3. TCR-T LIBRARY: ALAUNOS THERAPEUTICS INC
    • 11.3.1. PRODUCT DESCRIPTION
    • 11.3.2. RESEARCH AND DEVELOPMENT
    • 11.3.3. SAFETY AND EFFICACY
    • 11.3.4. PRODUCT AND DEVELOPMENTAL ACTIVITIES
  • 11.4. SCG101: SCG CELL THERAPY
    • 11.4.1. PRODUCT DESCRIPTION
    • 11.4.2. RESEARCH AND DEVELOPMENT
    • 11.4.3. SAFETY AND EFFICACY
  • 11.5. TK-8001: T-KNIFE GMBH
    • 11.5.1. PRODUCT DESCRIPTION
    • 11.5.2. RESEARCH AND DEVELOPMENT
    • 11.5.3. SAFETY AND EFFICACY
    • 11.5.4. PRODUCT AND DEVELOPMENTAL ACTIVITIES
  • 11.6. ECT 204: JW THERAPEUTICS
    • 11.6.1. PRODUCT DESCRIPTION
    • 11.6.2. RESEARCH AND DEVELOPMENT
    • 11.6.3. PRODUCT AND DEVELOPMENTAL ACTIVITIES
  • 11.7. JWATM 203: JW THERAPEUTICS
    • 11.7.1. PRODUCT DESCRIPTION
    • 11.7.2. PRODUCT AND DEVELOPMENTAL ACTIVITIES
  • 11.8. IMC I109V: IMMUNOCORE
    • 11.8.1. PRODUCT DESCRIPTION
    • 11.8.2. RESEARCH AND DEVELOPMENT
    • 11.8.3. SAFETY AND EFFICACY
    • 11.8.4. PRODUCT AND DEVELOPMENTAL ACTIVITIES
  • 11.9. IMCM113V: IMMUNOCORE
    • 11.9.1. PRODUCT DESCRIPTION
    • 11.9.2. SAFETY AND EFFICACY
    • 11.9.3. PRODUCT AND DEVELOPMENTAL ACTIVITIES
  • 11.10. MDG 1011: MEDIGENE AG
    • 11.10.1. PRODUCT DESCRIPTION
    • 11.10.2. SAFETY AND EFFICACY
    • 11.10.3. PRODUCT AND DEVELOPMENTAL ACTIVITIES
  • 11.11. TC-210: ADAPTIMMUNE THERAPEUTICS
    • 11.11.1. PRODUCT DESCRIPTION
    • 11.11.2. RESEARCH AND DEVELOPMENT
    • 11.11.3. SAFETY AND EFFICACY
    • 11.11.4. PRODUCT AND DEVELOPMENTAL ACTIVITIES
  • 11.12. TC-110: ADAPTIMMUNE THERAPEUTICS
    • 11.12.1. PRODUCT DESCRIPTION
    • 11.12.2. RESEARCH AND DEVELOPMENT
    • 11.12.3. SAFETY AND EFFICACY

12. PRODUCT AND DEVELOPMENTAL ACTIVITIES

  • 12.1. TBI 1301: TAKARA BIO
    • 12.1.1. PRODUCT DESCRIPTION
    • 12.1.2. RESEARCH AND DEVELOPMENT
    • 12.1.3. SAFETY AND EFFICACY
    • 12.1.4. PRODUCT AND DEVELOPMENTAL ACTIVITIES
  • 12.2. IMA402: IMMATICS
    • 12.2.1. PRODUCT DESCRIPTION
    • 12.2.2. RESEARCH AND DEVELOPMENT
    • 12.2.3. SAFETY AND EFFICACY
    • 12.2.4. PRODUCT AND DEVELOPMENTAL ACTIVITIES
  • 12.3. TAC01 HER2: TRIUMVIRA
    • 12.3.1. PRODUCT DESCRIPTION
    • 12.3.2. RESEARCH AND DEVELOPMENT
    • 12.3.3. SAFETY AND EFFICACY
  • 12.4. TAC01 CLDN18.2: TRIUMVIRA
    • 12.4.1. PRODUCT DESCRIPTION
    • 12.4.2. RESEARCH AND DEVELOPMENT
    • 12.4.3. SAFETY AND EFFICACY
  • 12.5. HBV ANTIGEN SPECIFIC TCR REDIRECTED T-CELL: LION TCR
    • 12.5.1. PRODUCT DESCRIPTION
    • 12.5.2. RESEARCH AND DEVELOPMENT
    • 12.5.3. SAFETY AND EFFICACY
    • 12.5.4. PRODUCT AND DEVELOPMENTAL ACTIVITIES
  • 12.6. TC-E202: TCRCURE BIOTECH
    • 12.6.1. PRODUCT DESCRIPTION
    • 12.6.2. RESEARCH AND DEVELOPMENT
    • 12.6.3. PRODUCT AND DEVELOPMENTAL ACTIVITIES

13. EARLY-STAGE PRODUCTS (PHASE I)

  • 13.1. COMPARATIVE ANALYSIS
  • 13.2. TSC-100: TSCAN THERAPEUTICS
    • 13.2.1. PRODUCT DESCRIPTION
    • 13.2.2. RESEARCH AND DEVELOPMENT
    • 13.2.3. SAFETY AND EFFICACY
  • 13.3. TSC-200: TSCAN THERAPEUTICS
    • 13.3.1. PRODUCT DESCRIPTION
    • 13.3.2. RESEARCH AND DEVELOPMENT
  • 13.4. IMA201: IMMATICS
    • 13.4.1. PRODUCT DESCRIPTION
    • 13.4.2. RESEARCH AND DEVELOPMENT
  • 13.5. IMA203: IMMATICS
    • 13.5.1. PRODUCT DESCRIPTION
    • 13.5.2. RESEARCH AND DEVELOPMENT
    • 13.5.3. SAFETY AND EFFICACY
  • 13.6. ADP-A2M10: ADAPTIMMUNE
    • 13.6.1. PRODUCT DESCRIPTION
    • 13.6.2. RESEARCH AND DEVELOPMENT
    • 13.6.3. SAFETY AND EFFICACY
    • 13.6.4. PRODUCT DEVELOPMENTAL ACTIVITY
  • 13.7. ADP-A2AFP: ADAPTIMMUNE
    • 13.7.1. PRODUCT DESCRIPTION
    • 13.7.2. RESEARCH AND DEVELOPMENT
    • 13.7.3. SAFETY AND EFFICACY
    • 13.7.4. PRODUCT DEVELOPMENTAL ACTIVITY
  • 13.8. CMV TCR-T: CHINA IMMUNOTECH
    • 13.8.1. PRODUCT DESCRIPTION
    • 13.8.2. RESEARCH AND DEVELOPMENT
    • 13.8.3. SAFETY AND EFFICACY
  • 13.9. IMA401: IMMATICS
    • 13.9.1. PRODUCT DESCRIPTION
    • 13.9.2. RESEARCH AND DEVELOPMENT
    • 13.9.3. SAFETY AND EFFICACY
    • 13.9.4. PRODUCT DEVELOPMENTAL ACTIVITIES
  • 13.10. BNT221: BIONTECH
    • 13.10.1. PRODUCT DESCRIPTION
    • 13.10.2. RESEARCH AND DEVELOPMENT
    • 13.10.3. SAFETY AND EFFICACY
  • 13.11. NT 125: NEOGENE THERAPEUTICS
    • 13.11.1. PRODUCT DESCRIPTION
    • 13.11.2. PRODUCT DEVELOPMENTAL ACTIVITIES
  • 13.12. NT-175: NEOGENE THERAPEUTICS
    • 13.12.1. PRODUCT DESCRIPTION
    • 13.12.2. RESEARCH AND DEVELOPMENT
    • 13.12.3. PRODUCT DEVELOPMENTAL ACTIVITIES
  • 13.13. LYL-845: LYELL IMMUNOPHARMA
    • 13.13.1. PRODUCT DESCRIPTION
    • 13.13.2. RESEARCH AND DEVELOPMENT
  • 13.14. BRL03: BIOSYNGEN
    • 13.14.1. PRODUCT DESCRIPTION
  • 13.15. TSC 101: TSCAN THERAPEUTICS
    • 13.15.1. PRODUCT DESCRIPTION
    • 13.15.2. RESEARCH AND DEVELOPMENT
    • 13.15.3. SAFETY AND EFFICACY
  • 13.16. AB-1015: ARSENALBIO
    • 13.16.1. PRODUCT DESCRIPTION
    • 13.16.2. RESEARCH AND DEVELOPMENT
    • 13.16.3. SAFETY AND EFFICACY
  • 13.17. TSC 204: TSCAN THERAPEUTICS
    • 13.17.1. PRODUCT DESCRIPTION
    • 13.17.2. RESEARCH AND DEVELOPMENT
  • 13.18. TSC 203: TSCAN THERAPEUTICS
    • 13.18.1. PRODUCT DESCRIPTION
    • 13.18.2. PRODUCT DEVELOPMENTAL ACTIVITY
  • 13.19. 800 TCR: T-CURE
    • 13.19.1. PRODUCT DESCRIPTION
    • 13.19.2. RESEARCH AND DEVELOPMENT
    • 13.19.3. PRODUCT DEVELOPMENTAL ACTIVITY
  • 13.20. 820 TCR: T-CURE
    • 13.20.1. PRODUCT DESCRIPTION
    • 13.20.2. RESEARCH AND DEVELOPMENT

14. IND-STAGE PRODUCTS

  • 14.1. COMPARATIVE ANALYSIS

15. PRECLINICAL-STAGE PRODUCTS

  • 15.1. COMPARATIVE ANALYSIS

16. DISCOVERY-STAGE PRODUCTS

  • 16.1. COMPARATIVE ANALYSIS

17. INACTIVE PRODUCTS

  • 17.1. COMPARATIVE ANALYSIS

18. STRATEGIC DEVELOPMENTS

  • 18.1. MERGERS & ACQUISITIONS
  • 18.2. PARTNERSHIPS & AGREEMENTS

19. UNMET NEEDS

LIST OF TABLES

  • TABLE 1: TOTAL ACTIVE PRODUCTS IN THE TCR THERAPY PIPELINE
  • TABLE 2: PRODUCTS IN VARIOUS PHASES
  • TABLE 3: EVALUATION BY ROUTE OF ADMINISTRATION
  • TABLE 4: EVALUATION BY MOLECULE TYPE
  • TABLE 5: EVALUATION BY PRODUCT TYPE
  • TABLE 6: EVALUATION BY THERAPY AREA
  • TABLE 7: LATE-STAGE PRODUCTS (PRE-REGISTRATION)
  • TABLE 8: CLINICAL TRIALS DESCRIPTION: ADP-A2M4
  • TABLE 9: GENERAL DESCRIPTION: ADP-A2M4
  • TABLE 10: LATE-STAGE PRODUCTS (PHASE III)
  • TABLE 11: CLINICAL TRIALS DESCRIPTION: IMC-F106C
  • TABLE 12: GENERAL DESCRIPTION: IMC-F106C
  • TABLE 13: MID-STAGE PRODUCTS (PHASE II/III)
  • TABLE 14: CLINICAL TRIALS DESCRIPTION: IMCGP100
  • TABLE 15: GENERAL DESCRIPTION: IMCGP100
  • TABLE 16: MID-STAGE PRODUCTS (PHASE II)
  • TABLE 17: CLINICAL TRIALS DESCRIPTION
  • TABLE 18: GENERAL DESCRIPTION: TAEST 16001
  • TABLE 19: CLINICAL TRIALS DESCRIPTION: GSK 3377794
  • TABLE 20: GENERAL DESCRIPTION: GSK 3377794
  • TABLE 21: CLINICAL TRIALS DESCRIPTION: ALT-801
  • TABLE 22: GENERAL DESCRIPTION: ALT-801
  • TABLE 23: CLINICAL TRIALS DESCRIPTION: KITE-439
  • TABLE 24: GENERAL DESCRIPTION: KITE-439
  • TABLE 25: CLINICAL TRIALS DESCRIPTION: KITE-718
  • TABLE 26: GENERAL DESCRIPTION: KITE-718
  • TABLE 27: EARLY-STAGE PRODUCTS (PHASE I/II)
  • TABLE 28: CLINICAL TRIALS DESCRIPTION: TC-510
  • TABLE 29: GENERAL DESCRIPTION: TC-510
  • TABLE 30: CLINICAL TRIALS DESCRIPTION: TCR-T LIBRARY
  • TABLE 31: GENERAL DESCRIPTION: TCR-T LIBRARY
  • TABLE 32: CLINICAL TRIALS DESCRIPTION: SCG101
  • TABLE 33: GENERAL DESCRIPTION: SCG101
  • TABLE 34: CLINICAL TRIALS DESCRIPTION: TK-8001
  • TABLE 35: GENERAL DESCRIPTION: TK-8001
  • TABLE 36: CLINICAL TRIALS DESCRIPTION: ECT204
  • TABLE 37: GENERAL DESCRIPTION: ECT204
  • TABLE 38: GENERAL DESCRIPTION: JWATM 203
  • TABLE 39: CLINICAL TRIALS DESCRIPTION: IMC-I109V
  • TABLE 40: GENERAL DESCRIPTION: IMC-I109V
  • TABLE 41: GENERAL DESCRIPTION: IMC M113V
  • TABLE 42: GENERAL DESCRIPTION: MDG 1011
  • TABLE 43: CLINICAL TRIALS DESCRIPTION: TC-210
  • TABLE 44: GENERAL DESCRIPTION: TC-210
  • TABLE 45: CLINICAL TRIALS DESCRIPTION: TC-110
  • TABLE 46: GENERAL DESCRIPTION: TC-110
  • TABLE 47: CLINICAL TRIALS DESCRIPTION: TBI 1301
  • TABLE 48: GENERAL DESCRIPTION: TBI 1301
  • TABLE 49: CLINICAL TRIALS DESCRIPTION: IMA402
  • TABLE 50: GENERAL DESCRIPTION: IMA402
  • TABLE 51: CLINICAL TRIALS DESCRIPTION: TAC01 HER2
  • TABLE 52: GENERAL DESCRIPTION: TAC01 HER2
  • TABLE 53: CLINICAL TRIALS DESCRIPTION: TAC01 CLDN18.2
  • TABLE 54: GENERAL DESCRIPTION: TAC01 CLDN18.2
  • TABLE 55: CLINICAL TRIALS DESCRIPTION: HBV ANTIGEN SPECIFIC TCR REDIRECTED T-CELL
  • TABLE 56: GENERAL DESCRIPTION: HBV ANTIGEN SPECIFIC TCR REDIRECTED T-CELL
  • TABLE 57: CLINICAL TRIALS DESCRIPTION: TC-E202
  • TABLE 58: GENERAL DESCRIPTION: TC-E202
  • TABLE 59: EARLY-STAGE PRODUCTS (PHASE I)
  • TABLE 60: CLINICAL TRIALS DESCRIPTION: TSC-100
  • TABLE 61: GENERAL DESCRIPTION: TSC-100
  • TABLE 62: CLINICAL TRIALS DESCRIPTION: TSC-200
  • TABLE 63: GENERAL DESCRIPTION: TSC-200
  • TABLE 64: CLINICAL TRIALS DESCRIPTION: IMA201
  • TABLE 65: GENERAL DESCRIPTION: IMA201
  • TABLE 66: CLINICAL TRIALS DESCRIPTION: IMA203
  • TABLE 67: GENERAL DESCRIPTION: IMA203
  • TABLE 68: CLINICAL TRIALS DESCRIPTION: ADP-A2M10
  • TABLE 69: GENERAL DESCRIPTION: ADP-A2M10
  • TABLE 70: CLINICAL TRIALS DESCRIPTION: ADP-A2AFP
  • TABLE 71: GENERAL DESCRIPTION: ADP-A2AFP
  • TABLE 72: CLINICAL TRIALS DESCRIPTION: CMV-TCR-T
  • TABLE 73: GENERAL DESCRIPTION: CMV-TCR-T
  • TABLE 74: CLINICAL TRIALS DESCRIPTION: IMA401
  • TABLE 75: GENERAL DESCRIPTION: IMA401
  • TABLE 76: CLINICAL TRIALS DESCRIPTION: BNT221
  • TABLE 77: GENERAL DESCRIPTION: BNT221
  • TABLE 78: GENERAL DESCRIPTION: NT-125
  • TABLE 79: CLINICAL TRIALS DESCRIPTION: NT-175
  • TABLE 80: GENERAL DESCRIPTION: NT-175
  • TABLE 81: CLINICAL TRIALS DESCRIPTION: LYL845
  • TABLE 82: GENERAL DESCRIPTION: LYL845
  • TABLE 83: GENERAL DESCRIPTION: BRL03
  • TABLE 84: CLINICAL TRIALS DESCRIPTION: TSC-101
  • TABLE 85: GENERAL DESCRIPTION: TSC-101
  • TABLE 86: CLINICAL TRIALS DESCRIPTION: AB-1015
  • TABLE 87: GENERAL DESCRIPTION: AB-1015
  • TABLE 88: CLINICAL TRIALS DESCRIPTION: TSC-204
  • TABLE 89: GENERAL DESCRIPTION: TSC-204
  • TABLE 90: GENERAL DESCRIPTION: TSC-203
  • TABLE 91: CLINICAL TRIALS DESCRIPTION: 800 TCR
  • TABLE 92: GENERAL DESCRIPTION: 800 TCR
  • TABLE 93: CLINICAL TRIALS DESCRIPTION: 820 TCR
  • TABLE 94: GENERAL DESCRIPTION: 820 TCR
  • TABLE 95: IND-STAGE PRODUCTS
  • TABLE 96: PRECLINICAL-STAGE PRODUCTS
  • TABLE 97: DISCOVERY-STAGE PRODUCTS
  • TABLE 98: INACTIVE-STAGE PRODUCTS
  • TABLE 99: LIST OF MERGERS & ACQUISITIONS
  • TABLE 100: LIST OF PARTNERSHIPS & AGREEMENTS

LIST OF FIGURES

  • FIGURE 1: TCR PROTEIN AND GENE STRUCTURE
  • FIGURE 2: GENE REARRANGEMENT AT THE TR LOCI
  • FIGURE 3: SIZE AND COMPOSITION OF THE PRE-SELECTION, NAIVE AND ANTIGEN-EXPERIENCED REPERTOIRES
  • FIGURE 4: SKEWING OF THE TCR REPERTOIRE IN HUMAN DISEASE
  • FIGURE 5: PROCESS OF TCR-ENGINEERED T-CELLS THERAPY
  • FIGURE 6: TCR SIGNALING
  • FIGURE 7: THREE TYPICAL PROCEDURES TO OBTAIN TCR SEQUENCE
  • FIGURE 8: PRODUCTS IN VARIOUS PHASES
  • FIGURE 9: EVALUATION BY ROUTE OF ADMINISTRATION
  • FIGURE 10: EVALUATION BY STAGE AND ROUTE OF ADMINISTRATION
  • FIGURE 11: EVALUATION BY MOLECULE TYPE
  • FIGURE 12: EVALUATION BY STAGE AND MOLECULE TYPE
  • FIGURE 13: EVALUATION BY PRODUCT TYPE
  • FIGURE 14: EVALUATION BY STAGE AND PRODUCT TYPE
  • FIGURE 15: EVALUATION BY THERAPY AREA
  • FIGURE 16: EVALUATION BY STAGE AND THERAPY AREA
  • FIGURE 17: LATE-STAGE PRODUCTS (PRE-REGISTRATION)
  • FIGURE 18: LATE-STAGE PRODUCTS (PHASE III)
  • FIGURE 19: MID-STAGE PRODUCTS (PHASE II/III)
  • FIGURE 20: MID-STAGE PRODUCTS (PHASE II)
  • FIGURE 21: EARLY-STAGE PRODUCTS (PHASE I/II)
  • FIGURE 22: EARLY-STAGE PRODUCTS (PHASE I)
  • FIGURE 23: IND-STAGE PRODUCTS
  • FIGURE 24: PRECLINICAL-STAGE PRODUCTS
  • FIGURE 25: DISCOVERY-STAGE PRODUCTS
  • FIGURE 26: INACTIVE STAGE PRODUCTS